CN103385912A - Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus - Google Patents
Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus Download PDFInfo
- Publication number
- CN103385912A CN103385912A CN2013103140324A CN201310314032A CN103385912A CN 103385912 A CN103385912 A CN 103385912A CN 2013103140324 A CN2013103140324 A CN 2013103140324A CN 201310314032 A CN201310314032 A CN 201310314032A CN 103385912 A CN103385912 A CN 103385912A
- Authority
- CN
- China
- Prior art keywords
- extract
- ramulus
- ethanol
- folium pithecellobii
- pithecellobii lucidi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 146
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 61
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 title claims abstract description 59
- 229960003085 meticillin Drugs 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 244000033373 Pithecellobium clypearia Species 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 86
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 63
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960000479 ceftriaxone sodium Drugs 0.000 claims abstract description 33
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims abstract description 33
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims abstract description 32
- 229960003376 levofloxacin Drugs 0.000 claims abstract description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003208 petroleum Substances 0.000 claims abstract description 11
- 238000002481 ethanol extraction Methods 0.000 claims description 59
- 230000003115 biocidal effect Effects 0.000 claims description 39
- 229960003276 erythromycin Drugs 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 claims 1
- 238000003810 ethyl acetate extraction Methods 0.000 claims 1
- 235000014666 liquid concentrate Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 15
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract description 15
- 206010070834 Sensitisation Diseases 0.000 abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 abstract description 13
- 230000008313 sensitization Effects 0.000 abstract description 13
- 239000000469 ethanolic extract Substances 0.000 abstract 3
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 239000006286 aqueous extract Substances 0.000 abstract 1
- 229940098008 erythrocin Drugs 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 description 40
- 238000012360 testing method Methods 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 22
- 108010059993 Vancomycin Proteins 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 229960003165 vancomycin Drugs 0.000 description 17
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 17
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 10
- 230000000249 desinfective effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000007619 statistical method Methods 0.000 description 10
- 239000002024 ethyl acetate extract Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004500 asepsis Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000013383 initial experiment Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011005 laboratory method Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012259 ether extract Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000005142 microbroth dilution method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 208000005119 Necrotizing Pneumonia Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses water, ethanol and ethanol aqueous extracts of traditional Chinese medicine pithecellobium clypearia and application of corresponding petroleum ether, ethyl acetate, normal butanol and a water extractants in preparation of medicines for treating methicillin-resistant staphylococcus aureus (MRSA) and antibiotics anti-MRSA sensitization medicines. Meanwhile, the invention further discloses a preparation method of the extracts or extractants. Experimental results show that water, 10% ethanol, 30% ethanol, 60% ethanol, 95% ethanol extracts of pithecellobium clypearia and corresponding ethyl acetate, normal butanol and water extractants have stronger anti-MRSA effect, wherein the activity of the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia is the strongest, and the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia has sensitization effect on erythrocin, ceftriaxone sodium, levofloxacin for treating MRSA.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, relate to the new purposes of Chinese herbal medicine Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) extract.
Background technology
As everyone knows, current bacterial resistance has become the great public health problem of global range, and antibiotic abuse is the major reason that causes bacterial resistance.Methicillin-resistant staphylococcus aureus (Methicillin-resistant Staphylococcus aureus, hereinafter to be referred as " MRSA ") have multi-drug resistant and with high incidence and high mortality, it is the important pathogenic bacteria that causes the diseases such as necrotizing pneumonia, serious septicemia, necrotizing fasciitis, be one of important pathogen of hospital infection and community's infection, to clinical treatment, brought great difficulty.The antimicrobial drug drug resistance of MRSA to the overwhelming majority, even the most effective vancomycin of present clinical antimicrobial agent is also started to occur drug resistance, in case MRSA develops into the degree to the general drug resistance of vancomycin, the patient who infects MRSA will face the desperate situation that pasts medical help.Therefore, the situation that the directed toward bacteria drug resistance is on the rise, searching, exploitation have antimicrobial agent MRSA, antibiotic had the antibacterials of sensitization, and be very urgent.
Ramulus Et Folium Pithecellobii Lucidi is dry sprout and the leaf of Mimosaceae Ramulus Et Folium Pithecellobii Lucidi platymiscium Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.), be area, Guangdong and Guangxi Provinces Chinese herbal medicine commonly used, be used for the treatment of the diseases such as upper respiratory tract infection, acute pharyngolaryngitis, bacillary dysentery.There are at present the water of the open Ramulus Et Folium Pithecellobii Lucidi of document and the simple extracting solution of ethanol to have antivirus action, but to the medicinal application of the extract of other purposes of said extracted liquid or additive method preparation report not.
Summary of the invention
The objective of the invention is to develop the new purposes of Ramulus Et Folium Pithecellobii Lucidi on pharmaceutical field.
One of purpose is, with Ramulus Et Folium Pithecellobii Lucidi water or ethanol or ethanol water solution extract for the preparation of methicillin-resistant staphylococcus aureus resistance medicine and antibiotic methicillin-resistant staphylococcus aureus resistance hypersitization medicine.
Two of purpose is further to optimize Ramulus Et Folium Pithecellobii Lucidi water or ethanol or ethanol water solution extract, the active stronger extract of exploitation.
Three of purpose is to disclose the preparation method of said extracted thing.
Technical scheme of the present invention:
One, the preparation method of Ramulus Et Folium Pithecellobii Lucidi extract of the present invention comprises the following steps:
1. get pithecellobium clypearia, water or ethanol or ethanol water extract, and reclaim solvent and obtain extractum, make Ramulus Et Folium Pithecellobii Lucidi water extract or ethanol extraction or ethanol water solution extract.
2. above-mentioned extractum thin up, then with petroleum ether or ethyl acetate or n-butanol extraction, get that extract is concentrated makes respectively corresponding Ramulus Et Folium Pithecellobii Lucidi extract.The composition of this extract is further optimized, and its drug effect obviously improves.The medical material weight that relates in preparation and the unit of solvent volume ratio, medical material weight is in gram, and solvent volume is in milliliter.
Two, above-mentioned Ramulus Et Folium Pithecellobii Lucidi extract is applied to the preparation of methicillin-resistant staphylococcus aureus resistance medicine as active component.
Three, above-mentioned Ramulus Et Folium Pithecellobii Lucidi extract is applied to the preparation of antibiotic methicillin-resistant staphylococcus aureus resistance hypersitization medicine as active component.Particularly as the sensitizer of erythromycin, ceftriaxone sodium, the anti-MRSA composition of medicine of levofloxacin.
The present invention is by extracting Ramulus Et Folium Pithecellobii Lucidi and separating, pharmacological action to each extract methicillin-resistant staphylococcus aureus resistance (MRSA) is screened, and carry out the associating drug sensitive test, investigate the anti-MRSA of Ramulus Et Folium Pithecellobii Lucidi and to the sensitization of the anti-MRSA of antibiotic.Experimental result shows: Ramulus Et Folium Pithecellobii Lucidi water, 10% ethanol, 30% ethanol, 60% ethanol, 95% ethanol extraction and corresponding ethyl acetate, n-butyl alcohol and water layer extract all have stronger anti-MRSA effect, wherein the acetic acid ethyl ester extract activity of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction is the strongest, and is strong 4 times with respect to the antibacterial action of the water extract without extraction; The acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction has sensitization to erythromycin, ceftriaxone sodium, the anti-MRSA of levofloxacin.
The present invention screens the pharmacological action of the methicillin-resistant staphylococcus aureus resistance of Ramulus Et Folium Pithecellobii Lucidi extract by following method.
With minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of micro-broth dilution method Ramulus Et Folium Pithecellobii Lucidi extract to methicillin-resistant staphylococcus aureus.
Bacterial strain: methicillin-resistant staphylococcus aureus (MRSA is numbered M1-M20) clinical separation strain 20 strains; Staphylococcus aureus reference culture (Sa, ATCC25923) provides by No.1 Hospital Affiliated to Zhongshan Univ.'s laboratory medicine section clinical microbiology laboratory technique chamber, detects through No.1 Hospital Affiliated to Zhongshan Univ.'s clinical microbiology laboratory technique chamber and confirms its drug resistance.
The MH broth bouillon: MH meat soup dry powder (Britain OXOID LTD.) 2.1g, be settled to 100ml, NaOH regulates pH to 7.0, and autoclaving is put 4 ℃ of refrigerators standby.
Method: the micro-broth dilution method of with reference to the U.S. state-run clinical trial standardization committee (NCCLS), recommending operates.
The present invention investigates the sensitization of erythromycin, ceftriaxone sodium, levofloxacin methicillin-resistant staphylococcus aureus resistance Ramulus Et Folium Pithecellobii Lucidi extract by following method.
Bacterial strain: methicillin-resistant staphylococcus aureus (MRSA is numbered M1-M20) clinical separation strain 100 strains; Staphylococcus aureus reference culture (Sa, ATCC25923) provides by No.1 Hospital Affiliated to Zhongshan Univ.'s laboratory medicine section clinical microbiology laboratory technique chamber, detects through No.1 Hospital Affiliated to Zhongshan Univ.'s clinical microbiology laboratory technique chamber and confirms its drug resistance.
The MH broth bouillon: MH meat soup dry powder (Britain OXOID LTD.) 2.1g, be settled to 100ml, NaOH regulates pH to 7.0, and autoclaving is put 4 ℃ of refrigerators standby.
Method: the checkerboard method of recommending with reference to the U.S. state-run clinical trial standardization committee (NCCLS) operates.
The invention has the beneficial effects as follows:
The effect that has methicillin-resistant staphylococcus aureus resistance (MRSA) with the product that the inventive method prepares, and erythromycin, ceftriaxone sodium, the anti-MRSA of levofloxacin had sensitization, can be used as natural antibacterial, antibiotic sensitizer, be applied to the industries such as food, medicine; Realize simultaneously the comprehensive utilization of Ramulus Et Folium Pithecellobii Lucidi plant and improve its added value.The alleged medicine of the present invention comprises that the people is with medicine and other medicine for animal.
Above-mentioned Ramulus Et Folium Pithecellobii Lucidi extract of the present invention can be used as the active component of anti-microbial type pharmaceutical preparation, makes tablet, capsule, slow releasing agent, injection, suppository, compound preparation etc.
The specific embodiment
Below further illustrate technical scheme of the present invention by specific embodiment.
Embodiment 1
Prepare Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof
Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) is provided by Guangzhou Huacheng pharmaceutical plant.Ramulus Et Folium Pithecellobii Lucidi 300g, water 3000ml decocts 2 times, each 2 hours, filters; Merging filtrate, concentrate to obtain extractum (water extract) 81.9g.Get extractum 54.6g, after water 200ml suspendible, with each 200ml, use respectively petroleum ether, ethyl acetate, n-butanol extraction, every kind of solvent extraction three times, merge respectively each extract, concentrate to obtain ligroin extraction 0.9g, ethyl acetate extract 14.8g, n-butanol extract 11.7g, water layer extract 27.1g.
Embodiment 2
The screening of the pharmacological action of Ramulus Et Folium Pithecellobii Lucidi water extract and extract methicillin-resistant staphylococcus aureus resistance (MRSA) thereof
1 experimental technique
1) mensuration of minimum inhibitory concentration (MIC):
Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof, erythromycin, ceftriaxone sodium, levofloxacin, vancomycin carry out respectively a series of doubling dilutions in the MH broth bouillon, regulating the inoculation bacterium is 1.0 * 10
5CFU/ml.Cultivating 24 hours for 35 ℃, is its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
2) mensuration of minimum bactericidal concentration (MBC):
From 1) pipette 50 μ l to blood plate the hole of asepsis growth, evenly coating, cultivated 24 hours for 35 ℃, colony counting, make initial experiment viable count minimizing 99.9% or the concentration of above needed minimum antibacterials be its minimum bactericidal concentration (MBC).
By measuring minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of medicine, and data are added up and drawn MIC
50, MIC
90, MBC
50, MBC
90, estimate the effect of medicine methicillin-resistant staphylococcus aureus resistance.
2 experimental results
Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof, four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) the results are shown in Table 1 to the extracorporeal bacteria inhibitor test of methicillin-resistant staphylococcus aureus.
Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof to the extracorporeal disinfecting result of the test of methicillin-resistant staphylococcus aureus in Table 2.
Through statistical analysis, Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof are to the In Vitro Bacteriostasis of methicillin-resistant staphylococcus aureus and the MIC of bactericidal assay
50, MIC
90, MBC
50, MBC
90In Table 3.
Through statistical analysis, the MIC of four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) to the bacteriostatic test of methicillin-resistant staphylococcus aureus
50, MIC
90In Table 4:
Table 1 Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof, the four kinds of antibiotic extracorporeal bacteria inhibitor test result to MRSA
Table 2 Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof the extracorporeal disinfecting result of the test to MRSA
Table 3 Ramulus Et Folium Pithecellobii Lucidi water extract and extract thereof are to the In Vitro Bacteriostasis of MRSA and the statistical result of bactericidal assay
The statistical result of four kinds of antibiotic of table 4 to the extracorporeal bacteria inhibitor test of MRSA
Experimental result shows, Ramulus Et Folium Pithecellobii Lucidi water extract and acetic acid ethyl ester extract thereof, n-butyl alcohol extract, water layer have methicillin-resistant staphylococcus aureus resistance (MRSA) effect.Wherein the activity of the anti-MRSA of acetic acid ethyl ester extract of water extract is the strongest.
Embodiment 3
Prepare Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof
Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) is provided by Guangzhou Huacheng pharmaceutical plant.Ramulus Et Folium Pithecellobii Lucidi 300g,, with 10% ethanol 3000ml reflux, extract, 2 times, each 2 hours, filter; Merging filtrate, concentrate to obtain extractum (10% ethanol extraction) 95.1g.Get extractum 63.4g, use respectively petroleum ether, ethyl acetate, n-butanol extraction, every kind of solvent extraction three times, each 200ml, merge respectively each extract, concentrate to obtain petroleum ether extract 1.2g, acetic acid ethyl ester extract 17.3g, n-butyl alcohol extract 16.3g, water layer extract 28.6g.
Embodiment 4
The screening of the pharmacological action of Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract methicillin-resistant staphylococcus aureus resistance (MRSA) thereof
1 experimental technique
3) mensuration of minimum inhibitory concentration (MIC):
Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof, erythromycin, ceftriaxone sodium, levofloxacin, vancomycin carry out respectively a series of doubling dilutions in the MH broth bouillon, regulating the inoculation bacterium is 1.0 * 10
5CFU/ml.Cultivating 24 hours for 35 ℃, is its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
4) mensuration of minimum bactericidal concentration (MBC):
From 1) pipette 50 μ l to blood plate the hole of asepsis growth, evenly coating, cultivated 24 hours for 35 ℃, colony counting, make initial experiment viable count minimizing 99.9% or the concentration of above needed minimum antibacterials be its minimum bactericidal concentration (MBC).
By measuring minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of medicine, and data are added up and drawn MIC
50, MIC
90, MBC
50, MBC
90, estimate the effect of medicine methicillin-resistant staphylococcus aureus resistance.
2 experimental results
Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof, four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) the results are shown in Table 5 to the extracorporeal bacteria inhibitor test of methicillin-resistant staphylococcus aureus.
Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof to the extracorporeal disinfecting result of the test of methicillin-resistant staphylococcus aureus in Table 6.
Through statistical analysis, Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of methicillin-resistant staphylococcus aureus and the MIC of bactericidal assay
50, MIC
90, MBC
50, MBC
90In Table 7.
Through statistical analysis, the MIC of four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) to the bacteriostatic test of methicillin-resistant staphylococcus aureus
50, MIC
90In Table 8:
Table 5 Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof, the four kinds of antibiotic extracorporeal bacteria inhibitor test result to MRSA
Table 6 Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof the extracorporeal disinfecting result of the test to MRSA
Table 7 Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of MRSA and the statistical result of bactericidal assay
The statistical result of four kinds of antibiotic of table 8 to the extracorporeal bacteria inhibitor test of MRSA
Experimental result shows, Ramulus Et Folium Pithecellobii Lucidi 10% ethanol extraction and acetic acid ethyl ester extract thereof, n-butyl alcohol extract, water layer have methicillin-resistant staphylococcus aureus resistance (MRSA) effect.Wherein the activity of the anti-MRSA of acetic acid ethyl ester extract of 10% ethanol extraction is the strongest.
Embodiment 5
Prepare Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof
Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) is provided by Guangzhou Huacheng pharmaceutical plant.Ramulus Et Folium Pithecellobii Lucidi 300g,, with 30% ethanol 3000ml reflux, extract, 2 times, each 2 hours, filter; Merging filtrate, concentrate to obtain extractum (30% ethanol extraction) 115.5g.Get extractum 77.0g, use respectively petroleum ether, ethyl acetate, n-butanol extraction, every kind of solvent extraction three times, each 200ml, merge respectively each extract, concentrate to obtain petroleum ether extract 1.6g, acetic acid ethyl ester extract 21.7g, n-butyl alcohol extract 17.6g, water layer extract 36.1g.
Embodiment 6
The screening of the pharmacological action of Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract methicillin-resistant staphylococcus aureus resistance (MRSA) thereof
1 experimental technique
5) mensuration of minimum inhibitory concentration (MIC):
Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof, erythromycin, ceftriaxone sodium, levofloxacin, vancomycin carry out respectively a series of doubling dilutions in the MH broth bouillon, regulating the inoculation bacterium is 1.0 * 10
5CFU/ml.Cultivating 24 hours for 35 ℃, is its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
6) mensuration of minimum bactericidal concentration (MBC):
From 1) pipette 50 μ l to blood plate the hole of asepsis growth, evenly coating, cultivated 24 hours for 35 ℃, colony counting, make initial experiment viable count minimizing 99.9% or the concentration of above needed minimum antibacterials be its minimum bactericidal concentration (MBC).
By measuring minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of medicine, and data are added up and drawn MIC
50, MIC
90, MBC
50, MBC
90, estimate the effect of medicine methicillin-resistant staphylococcus aureus resistance.
2 experimental results
Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof, four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) the results are shown in Table 9 to the extracorporeal bacteria inhibitor test of methicillin-resistant staphylococcus aureus.
Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof to the extracorporeal disinfecting result of the test of methicillin-resistant staphylococcus aureus in Table 10.
Through statistical analysis, Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of methicillin-resistant staphylococcus aureus and the MIC of bactericidal assay
50, MIC
90, MBC
50, MBC
90In Table 11.
Through statistical analysis, the MIC of four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) to the bacteriostatic test of methicillin-resistant staphylococcus aureus
50, MIC
90In Table 12:
Table 9 Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof, the four kinds of antibiotic extracorporeal bacteria inhibitor test result to MRSA
Table 10 Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof the extracorporeal disinfecting result of the test to MRSA
Table 11 Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of MRSA and the statistical result of bactericidal assay
The statistical result of four kinds of antibiotic of table 12 to the extracorporeal bacteria inhibitor test of MRSA
Experimental result shows, Ramulus Et Folium Pithecellobii Lucidi 30% ethanol extraction and acetic acid ethyl ester extract thereof, n-butyl alcohol extract, water layer have methicillin-resistant staphylococcus aureus resistance (MRSA) effect.Wherein the activity of the anti-MRSA of acetic acid ethyl ester extract of 30% ethanol extraction is the strongest.
Embodiment 7
Prepare Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof
Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) is provided by Guangzhou Huacheng pharmaceutical plant.Ramulus Et Folium Pithecellobii Lucidi 300g,, with 95% ethanol 3000ml reflux, extract, 2 times, each 2 hours, filter; Merging filtrate, concentrate to obtain extractum (95% ethanol extraction) 119.4g.Get extractum 79.6g, use respectively petroleum ether, ethyl acetate, n-butanol extraction, every kind of solvent extraction three times, each 200ml, merge respectively each extract, concentrate to obtain petroleum ether extract 2.3g, acetic acid ethyl ester extract 22.5g, n-butyl alcohol extract 23.3g, water layer extract 31.4g.
Embodiment 8
The screening of the pharmacological action of Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract methicillin-resistant staphylococcus aureus resistance (MRSA) thereof
1 experimental technique
7) mensuration of minimum inhibitory concentration (MIC):
Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof, erythromycin, ceftriaxone sodium, levofloxacin, vancomycin carry out respectively a series of doubling dilutions in the MH broth bouillon, regulating the inoculation bacterium is 1.0 * 10
5CFU/ml.Cultivating 24 hours for 35 ℃, is its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
8) mensuration of minimum bactericidal concentration (MBC):
From 1) pipette 50 μ l to blood plate the hole of asepsis growth, evenly coating, cultivated 24 hours for 35 ℃, colony counting, make initial experiment viable count minimizing 99.9% or the concentration of above needed minimum antibacterials be its minimum bactericidal concentration (MBC).
By measuring minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of medicine, and data are added up and drawn MIC
50, MIC
90, MBC
50, MBC
90, estimate the effect of medicine methicillin-resistant staphylococcus aureus resistance.
2 experimental results
Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof, four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) the results are shown in Table 13 to the extracorporeal bacteria inhibitor test of methicillin-resistant staphylococcus aureus.
Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof to the extracorporeal disinfecting result of the test of methicillin-resistant staphylococcus aureus in Table 14.
Through statistical analysis, Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of methicillin-resistant staphylococcus aureus and the MIC of bactericidal assay
50, MIC
90, MBC
50, MBC
90In Table 15.
Through statistical analysis, the MIC of four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) to the bacteriostatic test of methicillin-resistant staphylococcus aureus
50, MIC
90In Table 16:
Table 13 Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof, the four kinds of antibiotic extracorporeal bacteria inhibitor test result to MRSA
Table 14 Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof the extracorporeal disinfecting result of the test to MRSA
Table 15 Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of MRSA and the statistical result of bactericidal assay
The statistical result of four kinds of antibiotic of table 16 to the extracorporeal bacteria inhibitor test of MRSA
Experimental result shows, Ramulus Et Folium Pithecellobii Lucidi 95% ethanol extraction and acetic acid ethyl ester extract thereof, n-butyl alcohol extract, water layer have methicillin-resistant staphylococcus aureus resistance (MRSA) effect.Wherein the activity of the anti-MRSA of acetic acid ethyl ester extract of 95% ethanol extraction is the strongest.
Embodiment 9
Prepare Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and extract thereof
Ramulus Et Folium Pithecellobii Lucidi (Pithecellobium clypearia Benth.) is provided by Guangzhou Huacheng pharmaceutical plant.Ramulus Et Folium Pithecellobii Lucidi 300g breaks into coarse powder, with 60% ethanol 3000ml, refluxes 2 times, each 2 hours, filters; Merging filtrate, concentrate to obtain extractum (60% ethanol extraction) 133.8g.Get extractum 89.2g, after water 200ml suspendible, with each 200ml, use respectively petroleum ether, ethyl acetate, n-butanol extraction, every kind of solvent extraction three times, merge respectively each extract, concentrate to obtain ligroin extraction 2.3g, ethyl acetate extract 26.2g, n-butanol extract 19.5g, water layer extract 41.1g.
Embodiment 10
The screening of the pharmacological action of Ramulus Et Folium Pithecellobii Lucidi 60% extract and extract methicillin-resistant staphylococcus aureus resistance thereof
1 experimental technique
9) mensuration of minimum inhibitory concentration (MIC):
Ramulus Et Folium Pithecellobii Lucidi extract, erythromycin, ceftriaxone sodium, levofloxacin, vancomycin carry out respectively a series of doubling dilutions in the MH broth bouillon, regulating the inoculation bacterium is 1.0 * 10
5CFU/ml.Cultivating 24 hours for 35 ℃, is its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
10) mensuration of minimum bactericidal concentration (MBC):
From 1) pipette 50 μ l to blood plate the hole of asepsis growth, evenly coating, cultivated 24 hours for 35 ℃, colony counting, make initial experiment viable count minimizing 99.9% or the concentration of above needed minimum antibacterials be its minimum bactericidal concentration (MBC).
By measuring minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of medicine, and data are added up and drawn MIC
50, MIC
90, MBC
50, MBC
90, estimate the effect of medicine methicillin-resistant staphylococcus aureus resistance.
2 experimental results
Ramulus Et Folium Pithecellobii Lucidi extract and four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) the results are shown in Table 17 to the extracorporeal bacteria inhibitor test of methicillin-resistant staphylococcus aureus.
Ramulus Et Folium Pithecellobii Lucidi extract to the extracorporeal disinfecting result of the test of methicillin-resistant staphylococcus aureus in Table 18.
Through statistical analysis, Ramulus Et Folium Pithecellobii Lucidi extract is to the In Vitro Bacteriostasis of methicillin-resistant staphylococcus aureus and the MIC of bactericidal assay
50, MIC
90, MBC
50, MBC
90In Table 19.
Through statistical analysis, the MIC of four kinds of antibiotic (erythromycin, ceftriaxone sodium, levofloxacin, vancomycin) to the bacteriostatic test of methicillin-resistant staphylococcus aureus
50, MIC
90In Table 20:
Table 17 Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and extract thereof, the four kinds of antibiotic extracorporeal bacteria inhibitor test result to MRSA
Table 18 Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and extract thereof the extracorporeal disinfecting result of the test to MRSA
Table 19 Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and extract thereof are to the In Vitro Bacteriostasis of MRSA and the statistical result of bactericidal assay
The statistical result of four kinds of antibiotic of table 20 to the extracorporeal bacteria inhibitor test of MRSA
Experimental result shows, Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and acetic acid ethyl ester extract thereof, n-butyl alcohol extract, water layer have stronger methicillin-resistant staphylococcus aureus resistance (MRSA) effect.Wherein the activity of the anti-MRSA of the acetic acid ethyl ester extract of 60% ethanol extraction (being extract of the present invention) is the strongest.
Embodiment 11
The investigation of the acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction to the sensitization of erythromycin, ceftriaxone sodium, levofloxacin methicillin-resistant staphylococcus aureus resistance
1 experimental technique
Checkerboard method:
Adopt checkerboard method, the acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction, erythromycin (ERY), ceftriaxone sodium (CRO), levofloxacin (LVX) are carried out respectively a series of doubling dilutions in the MH broth bouillon, the concentration of adjusting bacteria suspension is 1.0 * 10
5CFU/mL, be inoculated in 96 hole aseptic culture plates, cultivated 24 hours the MIC of the medicine after the observation compatibility to methicillin-resistant staphylococcus aureus for 35 ℃.Be its minimum inhibitory concentration (MIC) without the concentration that precipitates the minimum antibacterials that occur.
According to formula
, (FIC≤two kinds of medicines of 0.5 expression present synergism to estimate Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract and the antibiotic interaction of Antibiotic combination by calculating section Mlc index (FIC); 0.5＜FIC≤two kinds of medicines of 1 expression present summation action; 1＜FIC≤two kinds of medicines of 2 expressions are without interaction; FIC＞two kinds of medicines of 2 expressions present antagonism), and find out acetic acid ethyl ester extract and the antibiotic best concentration ratio of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction according to the asepsis growth hole, finally estimate the drug effect of the acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction to the antibiotic sensitization.
2 experimental results
The acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and the FIC value of Antibiotic combination drug sensitive test are in Table 21.The acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and erythromycin are FIC≤0.5 to the result of 20 strain MRSA and a strain ATCC25923 drug combination, are synergism; Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract and ceftriaxone sodium are FIC=0.5 to the result of a strain ATCC25923 drug combination, are synergism; Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract and ceftriaxone sodium are 0.5＜FIC≤1 to the result of 20 strain MRSA drug combinations, are summation action; Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract and levofloxacin are FIC=1 to the result of 20 strain MRSA and a strain ATCC25923 drug combination, are summation action.
The acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction the results are shown in Table 22 to the sensitization of the anti-MRSA of antibiotic.Take M1 MRSA as example, the Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract of 100 μ g/ml and ceftriaxone sodium administering drug combinations, can be reduced to 256 μ g/ml (uniting the MIC while using) from 1024 μ g/ml (MIC while using separately) with the MIC of ceftriaxone.The experimental result demonstration, for all strain subjects, the acetic acid ethyl ester extract of Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction all can reduce the MIC of erythromycin, ceftriaxone sodium, levofloxacin.Illustrate that the Ramulus Et Folium Pithecellobii Lucidi ethyl acetate extract has the sensitization to the antibiotic methicillin-resistant staphylococcus aureus resistance
The acetic acid ethyl ester extract of table 21 Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction and the FIC value of Antibiotic combination medication
| Strain number | EA+CRO | EA+LVX | EA+ERY | Strain number | EA+CRO | EA+LVX | EA+ERY |
| M1 | 0.75 | 1 | 0.25 | M11 | 0.75 | 1 | 0.5 |
| M2 | 0.75 | 1 | 0.25 | M12 | 0.625 | 1 | 0.5 |
| M3 | 0.75 | 1 | 0.25 | M13 | 1 | 1 | 0.5 |
| M4 | 1 | 1 | 0.5 | M14 | 1 | 1 | 0.5 |
| M5 | 1 | 1 | 0.5 | M15 | 1 | 1 | 0.5 |
| M6 | 1 | 1 | 0.5 | M16 | 1 | 1 | 0.5 |
| M7 | 1 | 1 | 0.5 | M17 | 1 | 1 | 0.5 |
| M8 | 1 | 1 | 0.5 | M18 | 1 | 1 | 0.5 |
| M9 | 1 | 1 | 0.5 | M19 | 1 | 1 | 0.375 |
| M10 | 1 | 1 | 0.5 | M20 | 0.75 | 1 | 0.375 |
| ATCC25923 | 0.5 | 0.625 | 0.5 | ? | ? | ? | ? |
The sensitization of the acetic acid ethyl ester extract of table 22 Ramulus Et Folium Pithecellobii Lucidi 60% ethanol extraction to the anti-MRSA of antibiotic
| Strain number | EA | CRO | EA | LVX | EA | ERY |
| M1 | 100 | 1024→256 | 100 | 32→16 | 25 | 512→64 |
| M2 | 100 | 1024→256 | 100 | 32→16 | 25 | 512→64 |
| M3 | 100 | 1024→256 | 100 | 16→8 | 25 | 512→64 |
| M4 | 100 | 512→256 | 100 | 32→16 | 50 | 512→128 |
| M5 | 100 | 1024→512 | 100 | 32→16 | 50 | 512→128 |
| M6 | 100 | 1024→512 | 100 | 32→16 | 50 | 512→128 |
| M7 | 100 | 1024→512 | 100 | 32→16 | 50 | 512→128 |
| M8 | 100 | 512→256 | 100 | 8→4 | 50 | 256→64 |
| M9 | 100 | 64→32 | 100 | 8→4 | 50 | 256→64 |
| M10 | 100 | 128→64 | 100 | 4→2 | 50 | 512→128 |
| M11 | 100 | 1024→256 | 100 | 32→16 | 50 | 256→64 |
| M12 | 100 | 64→8 | 100 | 4→2 | 50 | 256→64 |
| M13 | 100 | 1024→512 | 100 | 16→8 | 50 | 256→64 |
| M14 | 100 | 64→32 | 100 | 8→4 | 50 | 64→16 |
| M15 | 100 | 1024→512 | 100 | 32→16 | 50 | 256→64 |
| M16 | 100 | 64→32 | 100 | 8→4 | 50 | 1024→256 |
| M17 | 100 | 64→32 | 100 | 4→2 | 50 | 1024→256 |
| M18 | 100 | 128→64 | 100 | 32→16 | 50 | 512→64 |
| M19 | 100 | 2560→1280 | 100 | 32→16 | 50 | 512→64 |
| M20 | 50 | 2560→1280 | 100 | 32→16 | 50 | 512→64 |
| ATCC25923 | 50 | 8→2 | 100 | 0.25→0.03 | 50 | 0.5→0.13 |
[0166]Experimental result shows, extract of the present invention and erythromycin are synergism, and itself and ceftriaxone, levofloxacin are respectively summation action.And extract of the present invention has stronger sensitization to erythromycin, ceftriaxone sodium, levofloxacin methicillin-resistant staphylococcus aureus resistance.
Claims (8)
1. Ramulus Et Folium Pithecellobii Lucidi extract, it is characterized in that this extract is prepared by following methods: get pithecellobium clypearia, the extraction with aqueous solution of water or ethanol or ethanol, reclaim solvent extractum processed, the extractum thin up, with petroleum ether or ethyl acetate or n-butanol extraction, extract concentrates to obtain Ramulus Et Folium Pithecellobii Lucidi extract again.
2. Ramulus Et Folium Pithecellobii Lucidi extract as claimed in claim 1, the preparation method that it is characterized in that this extract comprises the following steps: get pithecellobium clypearia, extract three times with 60% ethanol water than the ratio for 1:10 in medical material weight and solvent volume, reclaim solvent and obtain extractum, use equal-volume ethyl acetate extraction three times after the extractum thin up, combining extraction liquid concentrates and to obtain described Ramulus Et Folium Pithecellobii Lucidi extract.
3. the application of Ramulus Et Folium Pithecellobii Lucidi extract in preparing methicillin-resistant staphylococcus aureus resistance class medicine as claimed in claim 1 or 2.
4. the application of Ramulus Et Folium Pithecellobii Lucidi extract in preparing antibiotic methicillin-resistant staphylococcus aureus resistance hypersitization medicine as claimed in claim 1 or 2.
5. application as claimed in claim 4, is characterized in that, described is erythromycin or ceftriaxone sodium or levofloxacin at antibiotic.
6. Ramulus Et Folium Pithecellobii Lucidi water extract or ethanol extraction or the ethanol water solution extract application in preparing the methicillin-resistant staphylococcus aureus resistance medicine.
7. Ramulus Et Folium Pithecellobii Lucidi water extract or ethanol extraction or the ethanol water solution extract application in preparing antibiotic methicillin-resistant staphylococcus aureus resistance hypersitization medicine.
8. application as claimed in claim 7, is characterized in that, described is erythromycin or ceftriaxone sodium or levofloxacin at antibiotic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310314032.4A CN103385912B (en) | 2013-07-24 | 2013-07-24 | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310314032.4A CN103385912B (en) | 2013-07-24 | 2013-07-24 | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103385912A true CN103385912A (en) | 2013-11-13 |
| CN103385912B CN103385912B (en) | 2015-06-17 |
Family
ID=49530447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310314032.4A Active CN103385912B (en) | 2013-07-24 | 2013-07-24 | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103385912B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974018A (en) * | 2015-06-15 | 2015-10-14 | 沈阳药科大学 | Compounds extracted from traditional Chinese medicine Pithecellobium clypearia Benth. and use thereof |
| CN105816511A (en) * | 2016-05-10 | 2016-08-03 | 中山大学 | Application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine |
| CN105963339A (en) * | 2016-05-10 | 2016-09-28 | 中山大学 | Application of folium archidendri clypeariae extract in preparation of multidrug-resistant pseudomonas aeruginosa drug |
| CN105998153A (en) * | 2016-05-10 | 2016-10-12 | 中山大学 | Application of pithecellobium clypearia extract to preparation of drug for resisting generation of extended spectrum beta-lactamase escherichia coli |
| WO2017193635A1 (en) * | 2016-05-10 | 2017-11-16 | 中山大学 | Pithecellobium clypearia benth. extract and application for preparing anti-microbial agent |
| CN107970272A (en) * | 2017-12-22 | 2018-05-01 | 成都乾坤动物药业股份有限公司 | The purposes of pithecellobium clypearia or extract in treatment and/or the bronchopneumonic medicine of auxiliary treatment livestock and poultry is prepared |
| CN111012819A (en) * | 2019-12-31 | 2020-04-17 | 江西杏林白马药业有限公司 | A nanometer preparation of Pithecellobium clypearia extract and its preparation method |
| CN111317791A (en) * | 2020-02-27 | 2020-06-23 | 江西杏林白马药业股份有限公司 | Heat-clearing and stranguria-treating tablet and preparation method thereof |
| CN111904995A (en) * | 2020-08-04 | 2020-11-10 | 南方医科大学 | Application of prunella vulgaris combined antibiotic in preparation of medicine for resisting multidrug-resistant staphylococcus aureus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1795888A (en) * | 2004-12-29 | 2006-07-05 | 广州莱泰制药有限公司 | Application of Extractive of Abarema elliptica in use for preparing antiallergic medication, food and cosmetic |
| CN101940574A (en) * | 2010-07-23 | 2011-01-12 | 中国人民解放军第三军医大学 | Application of combination of combined catechin substances with antibacterial drugs |
-
2013
- 2013-07-24 CN CN201310314032.4A patent/CN103385912B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1795888A (en) * | 2004-12-29 | 2006-07-05 | 广州莱泰制药有限公司 | Application of Extractive of Abarema elliptica in use for preparing antiallergic medication, food and cosmetic |
| CN101940574A (en) * | 2010-07-23 | 2011-01-12 | 中国人民解放军第三军医大学 | Application of combination of combined catechin substances with antibacterial drugs |
Non-Patent Citations (2)
| Title |
|---|
| 郭晓宇: "云南石仙桃和猴耳环活性成分的研究", <<沈阳药科大学博士学位论文>> * |
| 韩宗其等: "中药成分联合抗生素抗MRSA作用的研究进展", <<中草药>> * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974018A (en) * | 2015-06-15 | 2015-10-14 | 沈阳药科大学 | Compounds extracted from traditional Chinese medicine Pithecellobium clypearia Benth. and use thereof |
| EP3456335A4 (en) * | 2016-05-10 | 2019-05-08 | Sun Yat-Sen University | Pithecellobium clypearia benth, extract and application for preparing anti-microbial agent |
| US11154582B2 (en) | 2016-05-10 | 2021-10-26 | Sun Yat-Sen University | Method of chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection |
| CN105998153A (en) * | 2016-05-10 | 2016-10-12 | 中山大学 | Application of pithecellobium clypearia extract to preparation of drug for resisting generation of extended spectrum beta-lactamase escherichia coli |
| WO2017193635A1 (en) * | 2016-05-10 | 2017-11-16 | 中山大学 | Pithecellobium clypearia benth. extract and application for preparing anti-microbial agent |
| CN105963339A (en) * | 2016-05-10 | 2016-09-28 | 中山大学 | Application of folium archidendri clypeariae extract in preparation of multidrug-resistant pseudomonas aeruginosa drug |
| CN105816511A (en) * | 2016-05-10 | 2016-08-03 | 中山大学 | Application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine |
| CN105816511B (en) * | 2016-05-10 | 2019-09-17 | 中山大学 | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-Multi-drug resistant Acinetobacter baumannii drug |
| CN105963339B (en) * | 2016-05-10 | 2019-09-17 | 中山大学 | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-multi-resistant Pseudomonas aeruginosa drug |
| CN105998153B (en) * | 2016-05-10 | 2019-09-17 | 中山大学 | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-ESBLs-producing bacteria Escherichia coli drug |
| US11491198B2 (en) | 2016-05-10 | 2022-11-08 | Sun Yat-Sen University | Method of chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection |
| CN107970272A (en) * | 2017-12-22 | 2018-05-01 | 成都乾坤动物药业股份有限公司 | The purposes of pithecellobium clypearia or extract in treatment and/or the bronchopneumonic medicine of auxiliary treatment livestock and poultry is prepared |
| CN111012819A (en) * | 2019-12-31 | 2020-04-17 | 江西杏林白马药业有限公司 | A nanometer preparation of Pithecellobium clypearia extract and its preparation method |
| CN111317791A (en) * | 2020-02-27 | 2020-06-23 | 江西杏林白马药业股份有限公司 | Heat-clearing and stranguria-treating tablet and preparation method thereof |
| CN111904995A (en) * | 2020-08-04 | 2020-11-10 | 南方医科大学 | Application of prunella vulgaris combined antibiotic in preparation of medicine for resisting multidrug-resistant staphylococcus aureus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103385912B (en) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103385912B (en) | Pithecellobium clypearia extracts and application of extract in preparation of medicines for treating methicillin-resistant staphylococcus aureus | |
| CN105963339B (en) | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-multi-resistant Pseudomonas aeruginosa drug | |
| CN103130865A (en) | Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof | |
| CN103690538B (en) | With the active Chinese medical extract of anti-poultry mycoplasma, Chinese medicine composition | |
| CN105816511A (en) | Application of pithecellobium clypearia extracts to preparation of multi-drug resistant acinetobacter baumannii medicine | |
| CN105456306B (en) | Rattan lycopod extract is preparing the application in antibacterial anti-inflammatory natural drug | |
| CN109384676A (en) | Isovaleryl shikonin and its purposes in preparation collaboration overriding resistance S. aureus L-forms drug | |
| CN104274454B (en) | A kind of anti-medicine resistant Staphylococcus aureus composition of medicine and purposes | |
| CN105998153B (en) | Ramulus Et Folium Pithecellobii Lucidi extract is preparing the application in anti-ESBLs-producing bacteria Escherichia coli drug | |
| CN105920082A (en) | Application of pitecollobium clypearia benth extract in preparing medicine for resisting extended-spectrum beta-lactamase (ESBL) producing klebsiella pneumoniae | |
| CN102068464B (en) | Antibacterial and antiviral effective part extract of medicated leaven and medicinal use thereof | |
| CN113318149B (en) | Jasminum extract and preparation method and application thereof | |
| CN103520323B (en) | Application of Nauclea officinalis extract to preparation of medicament for resisting methicillin-resistant Staphylococcus aureus | |
| CN102600276B (en) | Traditional Chinese medicine compound capable of eliminating drug resistance of escherichia coli as well as preparation method and application thereof | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| Abdulridha et al. | Antidiarrheal effect of Capparis spinosa fruits extract | |
| CN103385898A (en) | Method for preparing MRSA (methicillin-resistant Staphylococcus aureus)-resistant andrographis extract | |
| CN103432214B (en) | Preparation method and application of effective components of polygonum capitatum | |
| CN101084951B (en) | Medicine for treating diseases concerned with respiratory and preparation method and application thereof | |
| CN113813303B (en) | Application of cyclocarya paliurus leaf extract in preparation of antibacterial drug and/or antibacterial agent for inhibiting drug-resistant bacteria | |
| CN101156841B (en) | An antineoplastic new use of biphenyl acetic acid and its salt | |
| CN110917287A (en) | A medicinal plant extract | |
| CN103860669B (en) | A kind of pharmaceutical composition containing Radix Pulsatillae water extract and application thereof | |
| CN103040897A (en) | Application of Qingkailing active component radix isatidis extract to preparation of anti-multidrug-resistant bacterium medicine | |
| CN103083448A (en) | Rhubarb and phellodendron medicinal pair extract for synergistically improving tinea pedis resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200409 Address after: No.48 fotian North Road, Jiulong Town, Huangpu District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU HUACHENG PHARMACEUTICAL Co.,Ltd. Address before: 510275 Xingang West Road, Guangdong, Guangzhou, No. 135, No. Patentee before: SUN YAT-SEN University |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: No.48 fotian North Road, jiufo street, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd Address before: No.48 fotian North Road, Jiulong Town, Huangpu District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU HUACHENG PHARMACEUTICAL Co.,Ltd. |